Source: Clinical Trials Arena

UNITY: Unity reports topline outcomes from trial of diabetic macular oedema therapy

Unity Biotechnology has reported outcomes from its randomised Phase IIb ASPIRE study of intravitreal UBX1325 for diabetic macular oedema. The post Unity reports topline outcomes from trial of diabetic macular oedema therapy appeared first on Clinical Trials Arena.

Read full article »
Annual Revenue
$100K-5.0M
Employees
1-25
Anirvan Ghosh's photo - CEO of UNITY

CEO

Anirvan Ghosh

CEO Approval Rating

58/100

Read more